Search

Zai Lab Ltd ADR

Suletud

SektorTervishoid

26.42 4.72

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.23

Max

27.43

Põhinäitajad

By Trading Economics

Sissetulek

191K

-51M

Müük

6.7M

106M

Aktsiakasum

-0.46

Kasumimarginaal

-47.808

Töötajad

1,784

EBITDA

-2.1M

-46M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+55.45% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

805M

2.9B

Eelmine avamishind

21.7

Eelmine sulgemishind

26.42

Uudiste sentiment

By Acuity

34%

66%

79 / 340 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. sept 2026, 23:56 UTC

News

Entergy Corp settled its 2025 forward sale agreements, delivering over 11 million shares for $913 million. Shares are higher in after-market trading.

2. sept 2026, 23:51 UTC

News

Mitek Systems Inc. won first place in the Image category of the 2026 LivDet-Face competition, boosting shares significantly higher in after-hours trading.

2. sept 2026, 23:51 UTC

News
Social Media

Uber Technologies Inc. shares are higher in after-market hours following its abrupt exit from Nigeria and plans to lay off over 3,000 employees globally.

2. sept 2026, 23:51 UTC

News

Revolution Medicines shares rise in after-market trading following positive Phase 1/2 data on RASONQUE for advanced RAS mutant non-small cell lung cancer.

2. sept 2026, 23:51 UTC

News

NWPX Infrastructure acquires Serpentix Conveyor, enhancing its wastewater treatment portfolio. Shares are trading higher in after-market hours following the announcement.

2. sept 2026, 23:46 UTC

News
Social Media

Zoom Communications appoints Jeff Epstein to its Board of Directors, effective immediately. Shares are trading higher in after-market hours amid leadership changes.

2. sept 2026, 23:41 UTC

News
Correlated Moves

nCino Inc will participate in the Piper Sandler Growth Frontiers Conference on September 16, 2026. Shares are higher in after-market trading.

2. sept 2026, 23:36 UTC

News

Phreesia shares declined after reporting second-quarter revenues of $129.5 million, while earnings per share of $0.03 missed expectations of $0.09.

2. sept 2026, 23:31 UTC

News

Genworth Financial announced a $500 million share repurchase program, with shares trading higher in after-market hours.

2. sept 2026, 23:31 UTC

News

Capital Southwest Corp increased its credit facility commitments to $595 million and extended the maturity to September 2031. Shares are higher in after-market trading.

2. sept 2026, 23:26 UTC

News

Sprinklr Inc shares are higher in after-market trading ahead of a meeting with DA Davidson on September 10, signaling potential strategic discussions.

2. sept 2026, 23:16 UTC

News
Correlated Moves

Cytokinetics Inc shares are trading lower after-market following its investor conference announcements, with Ionis Pharmaceuticals' decline possibly impacting sentiment in the sector.

2. sept 2026, 23:06 UTC

News
Social Media

JPMorgan Chase has reduced financing to Jane Street amid competition in the bond market, with shares trading near unchanged in after-market hours.

2. sept 2026, 23:06 UTC

News

Johnson & Johnson will participate in the Deutsche Bank 2026 Healthcare Summit on September 17. Shares are higher in after-market trading following the announcement.

2. sept 2026, 23:06 UTC

News
Correlated Moves

The U.S. Justice Department disrupted the Sality botnet, linked to cryptocurrency theft, contributing to CrowdStrike's higher shares in after-market hours.

2. sept 2026, 23:02 UTC

News
Social Media
Event

Broadcom Inc. shares fell in after-market trading following third-quarter earnings. Fourth-quarter revenue guidance of $34.8 billion missed consensus expectations of $35.05 billion.

2. sept 2026, 23:02 UTC

News

C3.ai Inc reported a fiscal Q1 net loss of $92.8 million and projected second-quarter revenue below expectations, contributing to a decline in after-market hours.

2. sept 2026, 23:02 UTC

News
Event
Social Media

Five Below Inc. shares rose in after-market trading after strong Q2 earnings and a $600 million share repurchase program announcement. Revenue guidance was also raised.

2. sept 2026, 23:02 UTC

News
Social Media

Ultragenyx Pharmaceutical shares are lower in after-market hours following the failure of its Phase 3 Aspire study for apazunersen in Angelman syndrome.

2. sept 2026, 23:02 UTC

News
Social Media

Snowflake Inc's stock rose in after-market trading following strong Q2 results, with adjusted EPS of $0.62 and revenue of $1.55 billion exceeding expectations.

2. sept 2026, 23:02 UTC

News

Kroger Co shares traded lower in after-market hours following the appointment of Mark Ibbotson as Executive Vice President and Chief Store Operations Officer.

2. sept 2026, 23:02 UTC

News
Social Media

NetApp Inc. shares declined in after-market trading following its earnings report, despite record revenues of $2.03 billion and raised fiscal year 2027 guidance.

2. sept 2026, 23:02 UTC

News

Ollie's Bargain Outlet updated its fiscal year 2026 EPS guidance, projecting $4.570 to $4.650, exceeding the consensus estimate. Shares are higher in after-market trading.

2. sept 2026, 23:01 UTC

News
Social Media

AeroVironment secures a $464.8 million U.S. Army contract for laser systems, boosting after-market shares amid positive revenue growth projections of $2.7 billion by 2028.

2. sept 2026, 23:01 UTC

News

Mirion Technologies shares rose in after-market trading following CFO Brian Schopfer's purchase of 20,000 shares for $312,000, increasing his total ownership to 1.33 million shares.

2. sept 2026, 23:01 UTC

News

Matrix Service Co's stock is lower in after-market hours following a fourth-quarter earnings miss, with adjusted EPS at $0.16 against a $0.20 estimate.

2. sept 2026, 23:01 UTC

News

Argan Inc reported record revenue of $384 million and net income of $53.3 million in Q2, driving shares sharply higher in after-market hours.

2. sept 2026, 23:01 UTC

News
Social Media
Event

PVH Corp reported second-quarter adjusted EPS of $3.70, exceeding expectations. Shares are trading higher in after-market hours following the earnings announcement.

2. sept 2026, 23:01 UTC

News
Social Media

Methode Electronics reported a wider net loss of $11.4 million for Q1 fiscal 2027, leading shares to trade lower in after-market hours.

2. sept 2026, 23:01 UTC

News
Event
Social Media

Tillys Inc shares rose in after-hours trading following strong Q2 results, with EPS of $0.27 surpassing estimates and revenue of $163.5 million.

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

55.45% tõus

12 kuu keskmine prognoos

Keskmine 39.33 USD  55.45%

Kõrge 45 USD

Madal 36 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

79 / 340 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat